Lv1
100 积分 2025-03-04 加入
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
1个月前
已完结
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
1个月前
已完结
Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis
1个月前
已完结
Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma
2个月前
已完结
Antibody-drug conjugates in urothelial carcinoma: current status and future
2个月前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
2个月前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
2个月前
已完结
经膀胱前入路和经膀胱后入路机器人辅助前列腺癌根治术早期效果比较
3个月前
已完结
Sarcomatoid urothelial carcinoma: advances and challenges
4个月前
已关闭
高危非肌层浸润性膀胱癌的保膀胱策略研究进展
4个月前
已完结
皖公网安备34019202002308
